<p>波士顿，2026 年 2 月 10 日（全球新闻通讯社）——Galecto, Inc.（纳斯达克：GLTO）是一家专注于开发新型治疗药物以重新定义血液癌症患者治疗范式的生物制药公司，今天宣布其之前宣布的承销公开发行普通股的定价。Galecto 将以每股 19.00 美元的公开发行价格出售总计 14,473,685 股普通股。此外，Galecto 已授予承销商一个为期 30 天的选择权，以公开发行价格购买额外的 2,171,052 股普通股，扣除承销折扣和佣金。预计 Galecto 从此次发行中获得的总收益约为 2.75 亿美元，未扣除承销折扣和佣金及 Galecto 应支付的发行费用，并假设承销商未行使购买额外股份的选择权。</p>
<p>所有证券均由 Galecto 提供。此次发行预计将在 2026 年 2 月 12 日左右完成，具体以惯例的交割条件为准。</p>
<p>Jefferies、Leerink Partners、Evercore ISI 和 Guggenheim Securities 担任此次发行的联合账簿管理人。</p>
<p>与这些证券相关的自动生效的货架注册声明已于 2026 年 2 月 10 日提交给证券交易委员会（SEC）。此次发行仅通过书面招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与此次发行相关的初步招股说明书补充及随附招股说明书已提交给 SEC，并可在 SEC 网站 www.sec.gov 上获取。最终招股说明书补充及与此次发行相关的随附招股说明书将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供，届时可从以下机构获取：Jefferies LLC（注意：股权承销招股说明书部门，520 Madison Avenue, New York, New York 10022；电话：877-821-7388；或电子邮件：Prospectus_Department@Jefferies.com）；Leerink Partners LLC（注意：承销部门，53 State Street, 40th Floor, Boston, Massachusetts 02109；电话：800-808-7425 ext. 6105；或电子邮件：syndicate@leerink.com）；Evercore Group L.L.C.（注意：股权资本市场，55 East 52nd Street, 35th Floor, New York, New York 10055；电话：888-474-0200；或电子邮件：ecm.prospectus@evercore.com）；或 Guggenheim Securities, LLC（注意：股权承销部门，330 Madison Avenue, 8th Floor, New York, New York 10017；电话：212-518-9544；或电子邮件：GSEquityProspectusDelivery@guggenheimpartners.com）。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在任何此类州或其他司法管辖区的证券法下注册或合格的情况下。</p>
<p><strong>关于 Galecto, Inc.</strong></p>
<p>Galecto, Inc.是一家临床阶段的生物技术公司，正在推进一系列抗体治疗药物，以改变广泛的血液癌症的治疗。Galecto 的产品线包括一个高度差异化的突变钙网蛋白（mut-CALR）驱动的骨髓增生性肿瘤组合，针对必需性血小板增多症和骨髓纤维化。Galecto 的产品线还包括 GB3226，这是一种首创的临床前双重抑制剂，针对急性髓性白血病的多种遗传亚型，抑制 ENL-YEATS 和 FLT3。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明，除了纯粹的历史信息外，可能构成《联邦证券法》意义上的 “前瞻性声明”，包括根据 1995 年美国私人证券诉讼改革法的安全港条款的目的。这些前瞻性声明包括但不限于关于 Galecto 对发行完成的预期；关于发行的惯常成交条件的满足；以及与公司对其资产、产品线和业务未来的预期、希望、信念、意图或战略相关的明示或暗示声明。此外，任何提及预测、预期或其他对未来事件或情况的描述，包括任何基本假设的声明，都是前瞻性声明。这些前瞻性声明基于对未来发展及其潜在影响的当前预期和信念。无法保证影响公司的未来发展将是预期的那些。这些前瞻性声明涉及多种风险、不确定性（其中一些超出公司的控制范围）或其他假设，可能导致实际结果或表现与这些前瞻性声明所表达或暗示的结果有实质性差异。这些风险和不确定性包括但不限于与承销公开发行相关的惯常成交条件的满足，以及在公司最近向 SEC 提交的文件中描述的 “风险因素”、“关于前瞻性声明的警示信息” 或 “关于前瞻性声明的警示说明” 标题下的那些不确定性和因素。如果这些风险或不确定性中的一个或多个实现，或者公司的任何假设被证明不正确，实际结果可能在实质上与这些前瞻性声明中预测的结果有所不同。本新闻稿中的任何内容均不应被视为任何人对其中所列前瞻性声明将会实现的陈述，或对这些前瞻性声明所设想的任何结果将会实现的陈述。您不应对本新闻稿中的前瞻性声明过度依赖，这些声明仅在作出时有效，并且完全受此处警示声明的限制。公司不承担或接受对任何前瞻性声明进行更新或修订的任何义务。</p>
<p>媒体联系人：</p>
<p>Lia Dangelico</p>
<p>Deerfield Group</p>
<p>lia.dangelico@deerfieldgroup.com</p>
<p>投资者联系人：</p>
<p>Brian Ritchie</p>
<p>LifeSci Advisors</p>
<p>britchie@lifesciadvisors.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1qWTBNeU0zTkRJd016TXdJelV3TURBMk9UazVOdz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1qWTBNeU0zTkRJd016TXdJelV3TURBMk9UazVOdz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png"/></p>

医药突破 ETF - ALPS

基因改革 ETF - ARK

GLTO

<p>Galecto, Inc. 已将其承销的公开发行定价为每股 19.00 美元，共计 14,473,685 股，旨在筹集约 2.75 亿美元。此次发行包括承销商在 30 天内购买额外 2,171,052 股的选择权。该发行预计将在 2026 年 2 月 12 日左右完成，具体需遵循惯例条件。Jefferies、Leerink Partners、Evercore ISI 和 Guggenheim Securities 是联合账簿管理人。此公告是在向 SEC 提交有效的货架注册声明后发布的</p>

<p>BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto and assuming no exercise of the underwriters’ option to purchase additional shares.</p>
<div class="lb-trans"><p>波士顿，2026 年 2 月 10 日（全球新闻通讯社）——Galecto, Inc.（纳斯达克：GLTO）是一家专注于开发新型治疗药物以重新定义血液癌症患者治疗范式的生物制药公司，今天宣布其之前宣布的承销公开发行普通股的定价。Galecto 将以每股 19.00 美元的公开发行价格出售总计 14,473,685 股普通股。此外，Galecto 已授予承销商一个为期 30 天的选择权，以公开发行价格购买额外的 2,171,052 股普通股，扣除承销折扣和佣金。预计 Galecto 从此次发行中获得的总收益约为 2.75 亿美元，未扣除承销折扣和佣金及 Galecto 应支付的发行费用，并假设承销商未行使购买额外股份的选择权。</p>
</div><p>All of the securities are being offered by Galecto. The offering is expected to close on or about February 12, 2026, subject to customary closing conditions.</p>
<div class="lb-trans"><p>所有证券均由 Galecto 提供。此次发行预计将在 2026 年 2 月 12 日左右完成，具体以惯例的交割条件为准。</p>
</div><p>Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>Jefferies、Leerink Partners、Evercore ISI 和 Guggenheim Securities 担任此次发行的联合账簿管理人。</p>
</div><p>An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on February 10, 2026. This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and, when available, may be obtained from: Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; or email: Prospectus_Department@Jefferies.com); Leerink Partners LLC (Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109; telephone: 800-808-7425 ext. 6105; or email: syndicate@leerink.com); Evercore Group L.L.C. (Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; telephone: 888-474-0200; or email: ecm.prospectus@evercore.com); or Guggenheim Securities, LLC (Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017; telephone: 212-518-9544; or email: GSEquityProspectusDelivery@guggenheimpartners.com).</p>
<div class="lb-trans"><p>与这些证券相关的自动生效的货架注册声明已于 2026 年 2 月 10 日提交给证券交易委员会（SEC）。此次发行仅通过书面招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与此次发行相关的初步招股说明书补充及随附招股说明书已提交给 SEC，并可在 SEC 网站 www.sec.gov 上获取。最终招股说明书补充及与此次发行相关的随附招股说明书将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供，届时可从以下机构获取：Jefferies LLC（注意：股权承销招股说明书部门，520 Madison Avenue, New York, New York 10022；电话：877-821-7388；或电子邮件：Prospectus_Department@Jefferies.com）；Leerink Partners LLC（注意：承销部门，53 State Street, 40th Floor, Boston, Massachusetts 02109；电话：800-808-7425 ext. 6105；或电子邮件：syndicate@leerink.com）；Evercore Group L.L.C.（注意：股权资本市场，55 East 52nd Street, 35th Floor, New York, New York 10055；电话：888-474-0200；或电子邮件：ecm.prospectus@evercore.com）；或 Guggenheim Securities, LLC（注意：股权承销部门，330 Madison Avenue, 8th Floor, New York, New York 10017；电话：212-518-9544；或电子邮件：GSEquityProspectusDelivery@guggenheimpartners.com）。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在任何此类州或其他司法管辖区的证券法下注册或合格的情况下。</p>
</div><p><strong>About Galecto, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Galecto, Inc.</strong></p>
</div><p>Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.</p>
<div class="lb-trans"><p>Galecto, Inc.是一家临床阶段的生物技术公司，正在推进一系列抗体治疗药物，以改变广泛的血液癌症的治疗。Galecto 的产品线包括一个高度差异化的突变钙网蛋白（mut-CALR）驱动的骨髓增生性肿瘤组合，针对必需性血小板增多症和骨髓纤维化。Galecto 的产品线还包括 GB3226，这是一种首创的临床前双重抑制剂，针对急性髓性白血病的多种遗传亚型，抑制 ENL-YEATS 和 FLT3。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding Galecto’s expectations regarding the consummation of the offering; the satisfaction of customary closing conditions with respect to the offering; and express or implied statements relating to the Company’s expectations, hopes, beliefs, intentions or strategies regarding the future of its assets, pipeline and business. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the satisfaction of customary closing conditions related to the underwritten public offering and those uncertainties and factors described under the headings “Risk Factors,” “Cautionary Information Regarding Forward-Looking Statements” or “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿中的某些声明，除了纯粹的历史信息外，可能构成《联邦证券法》意义上的 “前瞻性声明”，包括根据 1995 年美国私人证券诉讼改革法的安全港条款的目的。这些前瞻性声明包括但不限于关于 Galecto 对发行完成的预期；关于发行的惯常成交条件的满足；以及与公司对其资产、产品线和业务未来的预期、希望、信念、意图或战略相关的明示或暗示声明。此外，任何提及预测、预期或其他对未来事件或情况的描述，包括任何基本假设的声明，都是前瞻性声明。这些前瞻性声明基于对未来发展及其潜在影响的当前预期和信念。无法保证影响公司的未来发展将是预期的那些。这些前瞻性声明涉及多种风险、不确定性（其中一些超出公司的控制范围）或其他假设，可能导致实际结果或表现与这些前瞻性声明所表达或暗示的结果有实质性差异。这些风险和不确定性包括但不限于与承销公开发行相关的惯常成交条件的满足，以及在公司最近向 SEC 提交的文件中描述的 “风险因素”、“关于前瞻性声明的警示信息” 或 “关于前瞻性声明的警示说明” 标题下的那些不确定性和因素。如果这些风险或不确定性中的一个或多个实现，或者公司的任何假设被证明不正确，实际结果可能在实质上与这些前瞻性声明中预测的结果有所不同。本新闻稿中的任何内容均不应被视为任何人对其中所列前瞻性声明将会实现的陈述，或对这些前瞻性声明所设想的任何结果将会实现的陈述。您不应对本新闻稿中的前瞻性声明过度依赖，这些声明仅在作出时有效，并且完全受此处警示声明的限制。公司不承担或接受对任何前瞻性声明进行更新或修订的任何义务。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系人：</p>
</div><p>Lia Dangelico</p>
<div class="lb-trans"><p>Lia Dangelico</p>
</div><p>Deerfield Group</p>
<div class="lb-trans"><p>Deerfield Group</p>
</div><p>lia.dangelico@deerfieldgroup.com</p>
<div class="lb-trans"><p>lia.dangelico@deerfieldgroup.com</p>
</div><p>Investor Contact:</p>
<div class="lb-trans"><p>投资者联系人：</p>
</div><p>Brian Ritchie</p>
<div class="lb-trans"><p>Brian Ritchie</p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>britchie@lifesciadvisors.com</p>
<div class="lb-trans"><p>britchie@lifesciadvisors.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1qWTBNeU0zTkRJd016TXdJelV3TURBMk9UazVOdz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1MjY0MyM3NDIwMzMwIzUwMDA2OTk5Nw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png"/></p>

Galecto 宣布 2.75 亿美元的承销公开发行定价 | GLTO 股票新闻